JPRN-jRCTs031190205已完成未知
An open-label study of the clinical effects of the hon-wasabi extract sulfinyl component, 6-MSITC, on myalgic encephalomyelitis / chronic fatigue syndrome - 6-MSITC MECFS
Oka Takakazu0 个研究点目标入组 15 人开始时间: 2020年2月12日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 15
研究概览
简要总结
This study suggests that 6-MSITC-containing supplements (9.6 mg of 6-MSITC per day) are a safe and effective ingredient for especially improving PS levels and cognitive function in patients with ME/CFS. It was also suggested to improve the frequency of headaches and myalgia and to improve vitality and overall sense of wellness of patients with this illness. Therefore, 6-MSITC-containing supplements may be a useful treatment option for ME/CFS patients.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 < 70age old（—）
- 性别
- All
入选标准
- •1. Those who can be diagnosed as ME / CFS, according to the CDC diagnostic criteria (Fukuda1994) and the Ministry of Health, Labor and Welfare research group clinical diagnostic criteria (2017)
- •2. Those who are 20 to 69 years old (regardless of gender)
- •3. The performance status (severity of fatigue) is 3 and more, according to the ME / CFS clinical diagnostic criteria (2017), Table 3.
- •4. Those who can fill in self-rating questionnaires by themselves
- •5. Those who can come to the hospital at least once a month
- •6.Those whose consent judgment ability is judged to be sufficient
排除标准
- •1. Those whose fatigue is due to known physical diseases (liver, kidney, heart, respiratory, endocrine, autoimmune, or malignant diseases, anemia, electrolyte abnormalities, etc.)
- •2. Women who are pregnant or breastfeeding, who may become pregnant or who wish to become pregnant during this study
- •3. Those who have taken or are currently taking supplements containing 6-MSITC
- •4. Those who are judged to be inappropriate by the principal investigator
研究者
相似试验
已完成
3 期
A 24 Week Efficacy Study of Inhaled Umeclidinium (UMEC) in Patients of Chronic Obstructive Pulmonary Disease (COPD) Using a Novel Dry Powder Inhaler (NDPI)Pulmonary Disease, Chronic ObstructiveNCT02184611GlaxoSmithKline308
已完成
2 期
A Safety and Efficacy Study in Subjects With Diabetic Neuropathic PainDiabetic Neuropathic PainNCT00548925AbbVie (prior sponsor, Abbott)124
已完成
3 期
Long-Term Safety of PRC-063 in Adolescents and Adults With ADHDADHDNCT02168127Rhodes Pharmaceuticals, L.P.360
已完成
3 期
An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's DiseaseParkinson's DiseaseNCT01096186Impax Laboratories, LLC617
撤回
2 期
Dose-finding Study of LIK066 Compared With Placebo or Sitagliptin to Evaluate Change in HbA1c in Patients With DiabetesType 2 Diabetes MellitusNCT01824264Novartis Pharmaceuticals